<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and Prevention, epub: 2019-6-6collection: 2019-10345583591received: 2019-2-1accepted: 2019-4-29(C) , Abstract Conventional" exact="influenza" post="vaccines need to be designed and manufactured yearly. However,"/>
 <result pre="there is an urgent need to develop universal vaccines against" exact="influenza" post="virus. Using nucleoprotein (NP) and extracellular domain of matrix"/>
 <result pre="extracellular domain of matrix protein 2 (M2e) genes from the" exact="influenza" post="A virus A/Beijing/30/95 (H3N2), we constructed four recombinant vaccinia"/>
 <result pre="A virus A/Beijing/30/95 (H3N2), we constructed four recombinant vaccinia virus-based" exact="influenza" post="vaccines carrying NP fused with one or four copies"/>
 <result pre="measured, and then the immunized mice were challenged with the" exact="influenza" post="A virus A/Puerto Rico/8/34 (PR8). NP-specific humoral response was"/>
 <result pre="4M2eNP fusion antigen may be employed to develop a universal" exact="influenza" post="vaccine. Electronic supplementary material The online version of this"/>
 <result pre="to authorized users. Keywords Influenza A virus (IAV) Cross-protection Recombinant" exact="vaccinia virus" post="Conserved antigen Introduction Seasonal influenza is an acute respiratory"/>
 <result pre="virus (IAV) Cross-protection Recombinant vaccinia virus Conserved antigen Introduction Seasonal" exact="influenza" post="is an acute respiratory infectious disease that can cause"/>
 <result pre="virus Conserved antigen Introduction Seasonal influenza is an acute respiratory" exact="infectious disease" post="that can cause serious health problems. Seasonal influenza epidemics"/>
 <result pre="respiratory infectious disease that can cause serious health problems. Seasonal" exact="influenza" post="epidemics caused by influenza A and B viruses result"/>
 <result pre="can cause serious health problems. Seasonal influenza epidemics caused by" exact="influenza" post="A and B viruses result in 3–5 million severe"/>
 <result pre="suffer from flu annually (World Health Organization, WHO 2019). Seasonal" exact="influenza" post="viruses undergo antigenic drift, which makes the conventional seasonal"/>
 <result pre="the vaccine strains mismatch with the epidemic strains. Therefore, seasonal" exact="influenza" post="vaccines must be updated regularly for effective prevention of"/>
 <result pre="for effective prevention of influenza. The production time for conventional" exact="influenza" post="vaccines can be lengthy. It takes 1–2 months to"/>
 <result pre="technology, followed by several more months for large-scale expansion of" exact="influenza" post="vaccine using an ample supply of specific pathogen-free (SPF)"/>
 <result pre="an ample supply of specific pathogen-free (SPF) chicken embryos. Generally," exact="influenza" post="vaccine production takes 3–6 months from the prediction of"/>
 <result pre="long-lasting immune responses (Erbelding et al.2018). Recently, great strides in" exact="influenza" post="vaccine research have been made using conserved antigens of"/>
 <result pre="influenza vaccine research have been made using conserved antigens of" exact="influenza" post="virus. The highly conserved internal protein nucleoprotein (NP) and"/>
 <result pre="domain of matrix protein 2 (M2e) can induce cross-protection against" exact="influenza" post="A virus, showing promise as candidate antigens for the"/>
 <result pre="promise as candidate antigens for the development of a broad-spectrum" exact="influenza" post="vaccine (Erbelding et al. 2018; Zhang et al.2015; Kui"/>
 <result pre="hydroxide gel protected mice from a lethal challenge with heterologous" exact="influenza" post="virus (Wang et al.2012). Therefore, vaccination with recombinant NM2e"/>
 <result pre="is a promising strategy for the development of a universal" exact="influenza" post="vaccine. However, a new expression system is required to"/>
 <result pre="required to further optimize the NP- and M2e-based vaccine. The" exact="vaccinia virus" post="(Tiantan strain) was developed in China as a vaccination"/>
 <result pre="~50 years, playing a key role in the eradication of" exact="smallpox" post="in China (Ruan 2013). The Tiantan strain has favorable"/>
 <result pre="Using the TK gene system of the Tiantan strain, this" exact="vaccinia virus" post="has been developed successfully as a viral vector for"/>
 <result pre="a viral vector for various vaccine applications (Ruan 2013) including" exact="hepatitis" post="B virus (Chuai et al.2018), hepatitis C virus (Wen"/>
 <result pre="applications (Ruan 2013) including hepatitis B virus (Chuai et al.2018)," exact="hepatitis" post="C virus (Wen et al.2013), and severe acute respiratory"/>
 <result pre="(Chuai et al.2018), hepatitis C virus (Wen et al.2013), and" exact="severe acute respiratory syndrome" post="coronavirus vaccines (Yan et al. 2009). We have developed"/>
 <result pre="vaccinia viruses based on NP, M1, M2, and PB1 of" exact="influenza" post="A virus (Huang et al. 2012; Wang et al.2007,"/>
 <result pre="well as protective effect against lethal challenge with a heterologous" exact="influenza" post="virus. Materials and Methods Materials β-Gal (40-1a) monoclonal antibody"/>
 <result pre="Ltd. Co. (Beijing, China). Viruses Vaccinia virus (Tiantan strain) and" exact="influenza" post="A virus A/Puerto Rico/8/34 (PR8) (H1N1) (Wang et al."/>
 <result pre="and titrated in primary chicken embryo fibroblasts (CEFs). The PR8" exact="influenza" post="virus was propagated in 9-day-old chicken embryos at 34"/>
 <result pre="until use. Mouse 50% lethal dose (MLD50) titer of the" exact="influenza" post="virus PR8 was assessed in BALB/c mice before conducting"/>
 <result pre="pJSC1175 contains two DNA fragments (TKL and TKR) derived from" exact="vaccinia virus" post="Tiantan strain to facilitate homologous recombination with vaccinia virus"/>
 <result pre="from vaccinia virus Tiantan strain to facilitate homologous recombination with" exact="vaccinia virus" post="in host cells. Between the two homology arms, there"/>
 <result pre="the two homology arms, there are p11 late promoter of" exact="vaccinia virus" post="to regulate the lacZ gene and p7.5 early/late promoter"/>
 <result pre="to regulate the lacZ gene and p7.5 early/late promoter of" exact="vaccinia virus" post="to regulate the target genes. The pJSC1175 was linearized"/>
 <result pre="amino acids) and the succeeding M2e (23 amino acids) from" exact="influenza" post="A virus, A/Beijing/30/95 (H3N2) (BJ95) (Wang et al. 2012)."/>
 <result pre="by Wang et al. (2015). Briefly, CEFs were infected with" exact="vaccinia virus" post="Tiantan strain at a multiplicity of infection of 0.01–0.1,"/>
 <result pre="by blue-white selection. Viral DNA was isolated from each recombinant" exact="vaccinia virus" post="to confirm the presence of fusion genes (NPM2e, M2eNP,"/>
 <result pre="produced on a large scale in CEFs. The control recombinant" exact="vaccinia virus" post="RVJ1175 was generated using the same method with the"/>
 <result pre="mouse monoclonal antibody (MAb) against β-Gal (40-1a), mouse MAb against" exact="influenza" post="A virus M2 (14C2), and mouse MAb against influenza"/>
 <result pre="against influenza A virus M2 (14C2), and mouse MAb against" exact="influenza" post="A virus NP (5D8). The signals were then visualized"/>
 <result pre="length of NPs. The NP and M2e gene fragments of" exact="influenza" post="A virus A/Beijing/30/95 (H3N2) were joined to create NPM2e,"/>
 <result pre="shown). Each confirmed plasmid was transfected into CEFs infected by" exact="vaccinia virus" post="Tiantan strain to facilitate homologous DNA recombination between plasmid"/>
 <result pre="RVJ-M2eNP, RVJ-4M2eNP, and RVJ-4M2eNPs were screened by blue-white selection. The" exact="vaccinia virus" post="DNA was extracted to amplify the target gene fragments"/>
 <result pre="vaccinia viruses. Except the control virus RVJ1175, all other recombinant" exact="vaccinia virus" post="expressed M2e and NP in the infected cells. It"/>
 <result pre="by mouse monoclonal antibodies to detect β-galactosidase (β-Gal) (upper panel)," exact="influenza" post="NP (middle panel), and M2e (lower panel), followed by"/>
 <result pre="of BALB/c mice were immunized with 107 PFU of recombinant" exact="vaccinia virus" post="at week 0 and 4. Ten days after the"/>
 <result pre="measure the cellular immune response. Mice immunized with the recombinant" exact="vaccinia virus" post="RVJ-NPM2e and RVJ-M2eNP showed strong antibody responses against NP,"/>
 <result pre="compared with RVJ-M2eNP. Except the control virus, all other recombinant" exact="vaccinia virus" post="seemed to induce M2e-specific cellular immune responses (Fig. 3B)."/>
 <result pre="second immunization, BALB/c mice were challenged with 20 MLD50 of" exact="influenza" post="A virus PR8, and then weight loss and survival"/>
 <result pre="three groups (Fig. 4B). Fig. 4 Protective efficacy of recombinant" exact="vaccinia virus" post="containing NP and M2e genes against 20 MLD50 of"/>
 <result pre="with recombinant vaccinia viruses and challenged with 20 MLD50 of" exact="influenza" post="virus strain PR8. Among them, mice immunized with recombinant"/>
 <result pre="influenza virus strain PR8. Among them, mice immunized with recombinant" exact="vaccinia virus" post="RVJ1175 served as vector control. Mice were monitored daily"/>
 <result pre="Discussion The extracellular domain of M2e is highly conserved among" exact="influenza" post="A virus subtypes (Muñoz-Medina et al.2015; Zebedee and Lamb"/>
 <result pre="as a target antigen in the development of a universal" exact="influenza" post="vaccine. In the present study, a single M2e induced"/>
 <result pre="stronger cross-protection than that of other groups against heterosubtypic H1N1" exact="influenza" post="virus challenge (Fig. 4B, RVJ-4M2eNP, RVJ-4M2eNPs). It had been"/>
 <result pre="by antibody-dependent cell-mediated cytotoxicity (ADCC), although it could not neutralize" exact="influenza" post="virus (Kim et al. 2017; Lee et al.2015). Besides,"/>
 <result pre="also been used as a target antigen to develop universal" exact="influenza" post="vaccines (Huang et al.2012; Li et al.2013; Wang et"/>
 <result pre="in BALB/c mouse. Previous research proved that human MAb against" exact="influenza" post="NP played an important role in fighting low-dose infection"/>
 <result pre="NP played an important role in fighting low-dose infection of" exact="influenza" post="virus (Fujimoto et al.2016), and NP might exert a"/>
 <result pre="played important roles in protection. NP-specific antibody could not neutralize" exact="influenza" post="virus just as M2e. However, it may protect animals"/>
 <result pre="peptides (Fig. 3C, RVJ-M2eNP). Significant progress is made to develop" exact="influenza" post="vaccine using viral vectors (Kim et al.2013; Li et"/>
 <result pre="Several recombinant viral vaccines have been constructed based on modified" exact="vaccinia virus" post="Ankara expressing HA, NP, M1, and PB1 antigens (Coughlan"/>
 <result pre="studies to develop recombinant viral vaccines. In this study, the" exact="vaccinia virus" post="Tiantan strain was used to construct recombinant vaccinia viruses"/>
 <result pre="vaccinia viruses expressing fusion antigens with different configurations. The recombinant" exact="vaccinia virus" post="expressing 4M2e and full-length NP fusion antigen induced strong"/>
 <result pre="successfully sometimes. Compared with an E. coli system, the recombinant" exact="vaccinia virus" post="system has characteristics such as high multiplication capacity, no"/>
 <result pre="al.2017). Future studies should focus on the development of universal" exact="influenza" post="vaccines containing multiple antigens to induce broad neutralizing responses,"/>
 <result pre="of the murine Th2 response to immunization with liposomal M2e" exact="influenza" post="vaccineVaccine2011294460446810.1016/j.vaccine.2011.04.04021545821 AltenburgAFMagnussonSEBosmanFStertmanLDe VriesRRimmelzwaanGFProtein- and modified vaccinia virus Ankara-based influenza"/>
 <result pre="immunization with liposomal M2e influenza vaccineVaccine2011294460446810.1016/j.vaccine.2011.04.04021545821 AltenburgAFMagnussonSEBosmanFStertmanLDe VriesRRimmelzwaanGFProtein- and modified" exact="vaccinia virus" post="Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in"/>
 <result pre="M2e influenza vaccineVaccine2011294460446810.1016/j.vaccine.2011.04.04021545821 AltenburgAFMagnussonSEBosmanFStertmanLDe VriesRRimmelzwaanGFProtein- and modified vaccinia virus Ankara-based" exact="influenza" post="virus nucleoprotein vaccines are differentially immunogenic in BALB/c miceClin"/>
 <result pre="Immunol2017190192810.1111/cei.1300428665497 AlvarezPZylbermanVGhersiGBoadoLPalaciosCGoldbaumFMattionNTandem repeats of the extracellular domain of matrix 2" exact="influenza" post="protein exposed in Brucella lumazine synthase decameric carrier molecule"/>
 <result pre="ChuaiXXieBChenHTanXWangWHuangBDengYLiWTanWThe immune response of rhesus macaques to novel vaccines comprising" exact="hepatitis" post="B virus S, PreS1, and Core antigensVaccine2018363740374610.1016/j.vaccine.2018.05.06129778513 CoughlanLSridharSPayneREdmansMMilicicAVenkatramanNLugonjaBCliftonLQiCFolegattiPMLawrieAMRobertsRde GraafHSukhtankarPFaustSNLewisDJMLambeTHillAVSGilbertSCHeterologous"/>
 <result pre="simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to" exact="influenza" post="virus A in healthy adultsEBioMedicine20182914615410.1016/j.ebiom.2018.02.01129519670 DhanwaniRZhouYHuangQVermaVDileepanMLyHLiangYA novel live Pichinde"/>
 <result pre="immunity after a booster doseJ Virol2016902551256010.1128/JVI.02705-154810697 Di MarioGSciaraffiaEFacchiniMGubinelliFSopranaEPanigadaMBernasconiVGarulliBSiccardiADonatelliICastrucciMRProtective immunity against" exact="influenza" post="in HLA-A2 transgenic mice by modified vaccinia virus Ankara"/>
 <result pre="MarioGSciaraffiaEFacchiniMGubinelliFSopranaEPanigadaMBernasconiVGarulliBSiccardiADonatelliICastrucciMRProtective immunity against influenza in HLA-A2 transgenic mice by modified" exact="vaccinia virus" post="Ankara vectored vaccines containing internal influenza proteinsPathog Glob Health2017111768210.1080/20477724.2016.127546528079473"/>
 <result pre="mice by modified vaccinia virus Ankara vectored vaccines containing internal" exact="influenza" post="proteinsPathog Glob Health2017111768210.1080/20477724.2016.127546528079473 EbrahimiSMDabaghianMTebianianMZabeh JaziMHIn contrast to conventional inactivated"/>
 <result pre="influenza proteinsPathog Glob Health2017111768210.1080/20477724.2016.127546528079473 EbrahimiSMDabaghianMTebianianMZabeh JaziMHIn contrast to conventional inactivated" exact="influenza" post="vaccines, 4 × M2e.HSP70c fusion protein fully protected mice against lethal"/>
 <result pre="protected mice against lethal dose of H1, H3 and H9" exact="influenza" post="A isolates circulating in IranVirology2012430637210.1016/j.virol.2012.04.01522595444 EmanuelEJWertheimerAWho should get influenza"/>
 <result pre="H9 influenza A isolates circulating in IranVirology2012430637210.1016/j.virol.2012.04.01522595444 EmanuelEJWertheimerAWho should get" exact="influenza" post="vaccine when not all canScience200631285485510.1126/science.112534716690847 ErbeldingEJPostDJStemmyEJRobertsPCAugustineADFergusonSPaulesCIGrahamBSFauciASA universal influenza vaccine:"/>
 <result pre="should get influenza vaccine when not all canScience200631285485510.1126/science.112534716690847 ErbeldingEJPostDJStemmyEJRobertsPCAugustineADFergusonSPaulesCIGrahamBSFauciASA universal" exact="influenza" post="vaccine: the strategic plan for the national institute of"/>
 <result pre="influenza vaccine: the strategic plan for the national institute of" exact="allergy" post="and infectious diseasesJ Infect Dis201821834735410.1093/infdis/jiy10329506129 FennerFHendersonDAAritaIJezekZLadnyiIDSmallpox and its eradication1988GenevaWorld"/>
 <result pre="Organization FujimotoYTomiokaYTakakuwaHUechiGIYabutaTOzakiKSuyamaHYamamotoSMorimatsuMMaiLQCross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal" exact="influenza" post="A virus infectionJ Gen Virol2016972104211610.1099/jgv.0.00051827260213 GuoLZhengMDingYLiDYangZWangHChenQSuiZFangFChenZProtection against multiple influenza"/>
 <result pre="lethal influenza A virus infectionJ Gen Virol2016972104211610.1099/jgv.0.00051827260213 GuoLZhengMDingYLiDYangZWangHChenQSuiZFangFChenZProtection against multiple" exact="influenza" post="A virus subtypes by intranasal administration of recombinant nucleoproteinArch"/>
 <result pre="JegaskandaSCoMDTCruzJSubbaraoKEnnisFATerajimaMInduction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal" exact="influenza" post="a viruses that are directed toward the nucleoproteinJ Infect"/>
 <result pre="vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against" exact="influenza" post="virus infectionPLoS ONE2013811110.1371/annotation/c8b2e360-b78a-4c2f-a1a3-c53325f18211 KimYJKoEJKimMCLeeYNKimKHJungYJKangSMRoles of antibodies to influenza A"/>
 <result pre="protection against influenza virus infectionPLoS ONE2013811110.1371/annotation/c8b2e360-b78a-4c2f-a1a3-c53325f18211 KimYJKoEJKimMCLeeYNKimKHJungYJKangSMRoles of antibodies to" exact="influenza" post="A virus hemagglutinin, neuraminidase, and M2e in conferring cross"/>
 <result pre="DNA vaccine induces protective cross-reactive T cell responses against heterologous" exact="influenza" post="virus in nonhuman primatesPLoS One201712e018978010.1371/journal.pone.018978029267331 KuiXGuanYZhouYYanSSZhangLLiHJSunMSProgress on adenovirus-vectored universal"/>
 <result pre="influenza virus in nonhuman primatesPLoS One201712e018978010.1371/journal.pone.018978029267331 KuiXGuanYZhouYYanSSZhangLLiHJSunMSProgress on adenovirus-vectored universal" exact="influenza" post="vaccinesHum Vaccines Immunother2015111209122210.1080/21645515.2015.1016674 LamereMWLamHMoquinAHaynesLLundFERandallTDKaminskiDAContributions of antinucleoprotein IgG to heterosubtypic"/>
 <result pre="Vaccines Immunother2015111209122210.1080/21645515.2015.1016674 LamereMWLamHMoquinAHaynesLLundFERandallTDKaminskiDAContributions of antinucleoprotein IgG to heterosubtypic immunity against" exact="influenza" post="virusJ Immunol20111864331433910.4049/jimmunol.100305721357542 LeeYNKimMCLeeYTKimYJKangSMMechanisms of cross-protection by influenza virus M2-based"/>
 <result pre="heterosubtypic immunity against influenza virusJ Immunol20111864331433910.4049/jimmunol.100305721357542 LeeYNKimMCLeeYTKimYJKangSMMechanisms of cross-protection by" exact="influenza" post="virus M2-based vaccinesImmune Netw20151521322110.4110/in.2015.15.5.21326557805 LeiHPengXJiaoHZhaoDOuyangJBroadly protective immunity against divergent"/>
 <result pre="influenza virus M2-based vaccinesImmune Netw20151521322110.4110/in.2015.15.5.21326557805 LeiHPengXJiaoHZhaoDOuyangJBroadly protective immunity against divergent" exact="influenza" post="viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein"/>
 <result pre="5 expressing NP from H5N1 virus provides broad immunity against" exact="influenza" post="A virusesJ Virol2013875985599310.1128/JVI.00120-1323514880 MaJYangFYuHZhouYLiGHuangMWenFTongGAn M2e-based synthetic peptide vaccine for"/>
 <result pre="influenza A virusesJ Virol2013875985599310.1128/JVI.00120-1323514880 MaJYangFYuHZhouYLiGHuangMWenFTongGAn M2e-based synthetic peptide vaccine for" exact="influenza" post="A virus confers heterosubtypic protection from lethal virus challengeVirol"/>
 <result pre="MacLeodMKDavidAJinNNogesLWangJKapplerJWMarrackPInfluenza nucleoprotein delivered with aluminium salts protects mice from an" exact="influenza" post="A virus that expresses an altered nucleoprotein sequencePLoS One20138e6177510.1371/journal.pone.006177523613928"/>
 <result pre="human nasopharynx-associated lymphoid tissue in vitro by modified vaccinia Ankara-vectored" exact="influenza" post="vaccinesVaccine2016341688169510.1016/j.vaccine.2016.02.02826902548 Muñoz-MedinaJESánchez-VallejoCJMéndez-TenorioAMonroy-MuñozIEAngeles-MartínezJSantos Coy-ArechavaletaASantacruz-TinocoCEGonzález-IbarraJAnguiano-HernándezYMGonzález-BonillaCRRamón-GallegosEDíaz-QuiñonezJAIn silico identification of highly conserved epitopes"/>
 <result pre="vaccinesVaccine2016341688169510.1016/j.vaccine.2016.02.02826902548 Muñoz-MedinaJESánchez-VallejoCJMéndez-TenorioAMonroy-MuñozIEAngeles-MartínezJSantos Coy-ArechavaletaASantacruz-TinocoCEGonzález-IbarraJAnguiano-HernándezYMGonzález-BonillaCRRamón-GallegosEDíaz-QuiñonezJAIn silico identification of highly conserved epitopes of" exact="influenza" post="A H1N1, H2N2, H3N2, and H5N1 with diagnostic and"/>
 <result pre="RotiMYangJBergerDHustonLJamesEAKwokWWHealthy human subjects have CD4+ T cells directed against H5N1" exact="influenza" post="virusJ Immunol20081801758176810.4049/jimmunol.180.3.175818209073 RuanLResearch and application of vaccinia virus Tiantan"/>
 <result pre="directed against H5N1 influenza virusJ Immunol20081801758176810.4049/jimmunol.180.3.175818209073 RuanLResearch and application of" exact="vaccinia virus" post="Tiantan strain vectorJ Microbes Infect2013828 SchotsaertMDe FiletteMFiersWSaelensXUniversal M2 ectodomain-based"/>
 <result pre="virus Tiantan strain vectorJ Microbes Infect2013828 SchotsaertMDe FiletteMFiersWSaelensXUniversal M2 ectodomain-based" exact="influenza" post="A vaccines: preclinical and clinical developmentsExpert Rev Vaccines2009849950810.1586/erv.09.619348565 TutykhinaIEsmagambetovIBagaevAPichuginALysenkoAShcherbininDSedovaELogunovDShmarovMAtaullakhanovRNaroditskyBGintsburgAVaccination"/>
 <result pre="potential of B and T epitope-enriched NP and M2 against" exact="influenza" post="A viruses from different clades and hostsPLoS One201813e019157410.1371/journal.pone.019157429377916 WangWHuangBDengYWangXTanWRuanLExpression"/>
 <result pre="A viruses from different clades and hostsPLoS One201813e019157410.1371/journal.pone.019157429377916 WangWHuangBDengYWangXTanWRuanLExpression of" exact="influenza" post="A3 virus (H3N2) M2 gene in vaccinia virus Tiantan"/>
 <result pre="One201813e019157410.1371/journal.pone.019157429377916 WangWHuangBDengYWangXTanWRuanLExpression of influenza A3 virus (H3N2) M2 gene in" exact="vaccinia virus" post="Tiantan strainChin J Virol200723377 WangWHuangBJiangTWangXQiXGaoYTanWRuanLRobust immunity and heterologous protection"/>
 <result pre="Tiantan strainChin J Virol200723377 WangWHuangBJiangTWangXQiXGaoYTanWRuanLRobust immunity and heterologous protection against" exact="influenza" post="in mice elicited by a novel recombinant NP-M2e fusion"/>
 <result pre="E. coliPLoS One20127e5248810.1371/journal.pone.005248823285063 WangWHuangBJiangTWangXQiXTanWRuanLMaximal immune response and cross protection by" exact="influenza" post="virus nucleoprotein derived from E. coli using an optimized"/>
 <result pre="M1 proteins as immunogens in DNA- and vaccinia virus-based universal" exact="influenza" post="A virus vaccines in miceClin Vaccine Immunol20152261863010.1128/CVI.00091-1525834017 WenBDengYChenHGuanJChuaiXRuanLKongWTanWthe novel"/>
 <result pre="A virus vaccines in miceClin Vaccine Immunol20152261863010.1128/CVI.00091-1525834017 WenBDengYChenHGuanJChuaiXRuanLKongWTanWthe novel replication-defective" exact="vaccinia virus" post="(Tiantan strain)-based hepatitis C virus vaccine induces robust immunity"/>
 <result pre="miceClin Vaccine Immunol20152261863010.1128/CVI.00091-1525834017 WenBDengYChenHGuanJChuaiXRuanLKongWTanWthe novel replication-defective vaccinia virus (Tiantan strain)-based" exact="hepatitis" post="C virus vaccine induces robust immunity in macaquesMol Ther2013211787179510.1038/mt.2013.12223774793"/>
 <result pre="Accessed 1 Feb 2019 YanKTanWWangHWangYZhangXLiYRuanLSARS-CoV spike proteins expressed by the" exact="vaccinia virus" post="Tiantan strain: secreted SQ protein induces robust neutralization antibody"/>
 <result pre="with different M2e epitope densities confers partial protection against H5N1" exact="influenza" post="A virus challenge in chickensIntervirology20115429029910.1159/00031944021228535 ZhangNZhengB-JLuLZhouYJiangSDuLAdvancements in the development"/>
 <result pre="virus challenge in chickensIntervirology20115429029910.1159/00031944021228535 ZhangNZhengB-JLuLZhouYJiangSDuLAdvancements in the development of subunit" exact="influenza" post="vaccinesMicrobes Infect20151712313410.1016/j.micinf.2014.12.00625529753 ZhaoGDuLXiaoWSunSLinYChenMKouZHeYLustigmanSJiangSZhengB-JZhouYInduction of protection against divergent H5N1 influenza"/>
 <result pre="subunit influenza vaccinesMicrobes Infect20151712313410.1016/j.micinf.2014.12.00625529753 ZhaoGDuLXiaoWSunSLinYChenMKouZHeYLustigmanSJiangSZhengB-JZhouYInduction of protection against divergent H5N1" exact="influenza" post="viruses using a recombinant fusion protein linking influenza M2e"/>
 <result pre="divergent H5N1 influenza viruses using a recombinant fusion protein linking" exact="influenza" post="M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvantVaccine2010287233724010.1016/j.vaccine.2010.08.04920732469"/>
 <result pre="using a recombinant fusion protein linking influenza M2e to Onchocerca" exact="volvulus" post="activation associated protein-1 (ASP-1) adjuvantVaccine2010287233724010.1016/j.vaccine.2010.08.04920732469 ZhaoGSunSDuLXiaoWRuZKouZGuoYYuHJiangSLoneYAn H5N1 M2e-based multiple"/>
 <result pre="lethal infection with pandemic 2009 H1N1 virusVirol J2010715110.1186/1743-422X-7-15120624292 ZhengMLiuFShenYWangSXuWFangFSunBXieZChenZCross-protection against" exact="influenza" post="virus infection by intranasal administration of nucleoprotein-based vaccine with"/>
</results>
